Vivos Inc (RDGL) — SEC Filings
Vivos Inc (RDGL) — 14 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 6 10-Q, 5 8-K, 2 10-K.
Overview
Vivos Inc (RDGL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: VIVOS INC (RDGL) reported a net loss of $1,987,503 for the nine months ended September 30, 2025, an increase from a net loss of $1,887,260 in the same period of 2024. Revenue for the nine months ended September 30, 2025, was $43,627, up from $23,000 in 2024, but gross profit turned into a gross loss
Sentiment Summary
Across 14 filings, the sentiment breakdown is: 2 bearish, 12 neutral. The dominant filing sentiment for Vivos Inc is neutral.
Filing Type Overview
Vivos Inc (RDGL) has filed 6 10-Q, 1 8-K/A, 5 8-K, 2 10-K with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (14)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 12, 2025 | 10-Q | Vivos Inc. Deepens Losses Amidst Strategic India Expansion | high |
| Sep 24, 2025 | 8-K/A | VIVOS INC. Files 8-K/A Amendment | medium |
| Sep 22, 2025 | 8-K | VIVOS INC. Reports Material Agreement, Officer Changes | medium |
| Sep 18, 2025 | 8-K | VIVOS INC. Secures $1.5M Private Placement | medium |
| Aug 13, 2025 | 10-Q | VIVOS INC's Losses Widen Amid R&D Spend, Cash Influx from Equity | high |
| May 9, 2025 | 10-Q | VIVOS INC Files Q1 2025 10-Q | medium |
| Mar 24, 2025 | 10-K | VIVOS INC Files 2024 10-K | medium |
| Feb 10, 2025 | 8-K | VIVOS INC. Files 8-K for Unregistered Equity Sale | medium |
| Nov 13, 2024 | 10-Q | VIVOS INC Files Q3 2024 10-Q | medium |
| Aug 13, 2024 | 10-Q | VIVOS INC Files Q2 2024 10-Q | medium |
| Jul 1, 2024 | 8-K | VIVOS INC. Files 8-K Report | low |
| May 9, 2024 | 10-Q | VIVOS INC Files 10-Q for Period Ending March 31, 2024 | low |
| Mar 25, 2024 | 8-K | VIVOS INC. Files 8-K: Agreements, Officer Changes, Financials | medium |
| Mar 18, 2024 | 10-K | VIVOS INC Files 2023 Annual Report on Form 10-K | medium |
Risk Profile
Risk Assessment: Of RDGL's 14 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $43,627 |
| Net Income | $(1,987,503) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $2,202,109 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Board of Directors
Industry Context
Vivos Inc. operates in the highly regulated biotechnology and human therapies sector. This industry is characterized by long development cycles, substantial R&D investment, and stringent regulatory oversight, particularly from bodies like the FDA. Success hinges on innovation, clinical trial outcomes, and securing significant funding to navigate these complex processes.
Top Tags
financials (5) · 10-Q (4) · material-agreement (3) · Medical Devices (2) · Oncology (2) · Going Concern (2) · Regulation A+ (2) · 10-K (2) · Medical Instruments (2) · Biotech (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenues, net | $43,627 | for the nine months ended September 30, 2025, up from $23,000 in 2024 |
| Gross (loss) profit | $(56,650) | for the nine months ended September 30, 2025, a decline from $2,301 gross profit in 2024 |
| Net loss | $(1,987,503) | for the nine months ended September 30, 2025, an increase from $(1,887,260) in 2024 |
| Cash | $2,202,109 | as of September 30, 2025, a slight decrease from $2,212,548 at December 31, 2024 |
| Proceeds from common stock | $1,500,000 | raised during the nine months ended September 30, 2025 |
| Accumulated deficit | $87,348,732 | as of September 30, 2025, indicating significant historical losses |
| Additional capital required | $9.0 million | over the next 36 months for FDA approval and clinical trials |
| Common stock outstanding | 454,664,957 | as of November 11, 2025, an increase from 440,873,806 at December 31, 2024 |
| Private Placement Proceeds | $1.5M | Gross proceeds expected from the offering |
| Closing Date | September 25, 2025 | Anticipated date for the completion of the private placement |
| Net Loss | $1.48M | Increased from $1.06M in prior year, indicating widening losses. |
| Revenue, Net | $41.7K | Increased from $18K, but remains very low for a public company. |
| Cash on Hand | $2.66M | Increased from $2.21M, but insufficient for future operations. |
| Annual Funding Required | $3M | Highlights the significant cash burn and going concern risk. |
| 36-Month Capital Need | $9M | Required for FDA approval and clinical trials, far exceeding current cash. |
Frequently Asked Questions
What are the latest SEC filings for Vivos Inc (RDGL)?
Vivos Inc has 14 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 5 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RDGL filings?
Across 14 filings, the sentiment breakdown is: 2 bearish, 12 neutral. The dominant sentiment is neutral.
Where can I find Vivos Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vivos Inc (RDGL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vivos Inc?
Key financial highlights from Vivos Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RDGL?
The investment thesis for RDGL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vivos Inc?
Key executives identified across Vivos Inc's filings include Board of Directors.
What are the main risk factors for Vivos Inc stock?
Of RDGL's 14 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Vivos Inc?
Forward guidance and predictions for Vivos Inc are extracted from SEC filings as they are enriched.